Checkmate Pharmaceuticals Obtains $20,000,000 Series A Round

  • Feed Type
  • Date
    8/13/2015
  • Company Name
    Checkmate Pharmaceuticals
  • Mailing Address
    1 Broadway 14th Floor Cambridge, MA 02142 USA
  • Company Description
    Checkmate Pharma is developing a new approach for cancer immunotherapy, by specifically activating the immune system to recognize and kill tumor cells throughout the body, without harming normal tissues. We have exclusively licensed a clinically validated virus-like particle (VLP) platform from Cytos Biotechnology Ltd (SIX:CYTN) for the field of oncology, that includes the clinical product (CYT003) and technologies related to oligonucleotide synthesis and VLP delivery.
  • Website
    http://www.checkmatepharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    These funds will further enable the company to develop additional generations of oligonucleotide-based products in the field of immuno-oncology.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    venBio

Trending on Xconomy